Filtered By:
Condition: Hemorrhagic Stroke

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 19785 results found since Jan 2013.

Hemorrhagic complications after removal of an external ventricular drain: A case report and literature review
CONCLUSION: Removal of an EVD is a safe procedure, with rare cases of hemorrhagic complications being reported. A case of a large hematoma that formed after the removal of an EVD is presented. Stricter follow-up protocols should be implemented to better estimate the risk of hemorrhage.PMID:37680933 | PMC:PMC10481797 | DOI:10.25259/SNI_415_2023
Source: Surgical Neurology International - September 8, 2023 Category: Neurosurgery Authors: Nikolaos Plakopitis Konstantinos Themistoklis Konstantinos Melanis Eleftherios Spartalis Panayiotis Patrikelis Themistoklis Papasilekas Source Type: research

Diffusion-Restricted Lesions of the Splenium: Clinical Presentation, Radiographic Patterns, and Patient Outcomes
Discussion Vascular DR lesions of the splenium were more common than CLOCCs and other etiologies in this cohort. While splenial DR lesions can present a clinical challenge, their associated clinical and radiographic characteristics may predict outcome and guide prognosis.
Source: Neurology Clinical Practice - September 8, 2023 Category: Neurology Authors: Stamm, B., Lineback, C. M., Tang, M., Jia, D. T., Chrenka, E., Sorond, F., Sabayan, B. Tags: MRI, DWI, All Cerebrovascular disease/Stroke Research Article Source Type: research

A prospective cohort study on decreased serum apelin-13 levels after human aneurysmal subarachnoid hemorrhage: associations with severity and prognosis
AbstractApelin-13 may have neuroprotective effects. We aimed to determine whether serum apelin-13 could serve as a potential biomarker for severity, delayed cerebral ischemia (DCI), and prognosis after human aneurysmal subarachnoid hemorrhage (aSAH). In this prospective, observational, cohort, single-center study of 139 patients with aSAH and 139 healthy individuals, serum apelin-13 levels were determined. The indicators of stroke severity were the Hunt-Hess scale and the modified Fisher grading scale. The prognostic parameters were DCI and 6-month worse prognosis (Extended Glasgow Outcome Scale scores of 1 –4). Using bi...
Source: Neurosurgical Review - September 8, 2023 Category: Neurosurgery Source Type: research

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Serum biomarkers to predict hemorrhagic transformation and ischemic stroke outcomes in a prospective cohort study
This study aimed to investigate the potential prognosis role of non-specific laboratory data at admission and baseline MMP-2 and MMP-9 serum levels in predicting HT risk, discharge, and 3-month follow-up status of IS patients. Data from 150 successive acute cerebral infarction patients were analyzed in a prospective cohort study. The active group included patients who developed HT during hospitalization (55 persons). There were no significant differences in age, gender distribution, time to admission, or time to blood sample collection for MMPs measurement between patients in the active and control groups. IS patients from...
Source: Journal of Medicine and Life - September 7, 2023 Category: General Medicine Authors: Elena Costru-Tasnic Mihail Gavriliuc Elena Manole Source Type: research

Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03178864.PMID:37675613 | DOI:10.1161/STROKEAHA.123.044113
Source: Atherosclerosis - September 7, 2023 Category: Cardiology Authors: Thalia S Field Vanessa Dizonno Mohammed A Almekhlafi Fouzi Bala Ibrahim Alhabli Hubert Wong Monica Norena Maria Karina Villaluna Princess King-Azote Namali Ratnaweera Steven Mancini Stephen C Van Gaal Laura K Wilson Brett R Graham Luciano A Sposato Dylan Source Type: research